JordanBerlinMD

Oncology • Nashville, TN

Gastrointestinal Cancer, Hematologic Oncology

Professor, Medicine, Vanderbilt University School of Medicine

Join to view full profile

Dr. Berlin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Berlin's full profile

Already have an account?

Office
3601 21st Ave S
Nashville, TN 37232
Phone+1 615-322-3000

Fax+1 615-343-7602

Education & Training

University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1992 - 1995
University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 1989 - 1992
University of Illinois College of MedicineClass of 1989

Certifications & Licensure

TN State Medical License 1999 - 2025
AL State Medical License 2020 - 2020
IL State Medical License 1995 - 1999
WI State Medical License 1992 - 1999
OH State Medical License 1991 - 1992
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
Nashville Lifestyles Magazine Castle Connolly, 2011, 2013-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Whos Who in Medicine and Healthcare Marquis Whos Who
Join now to see all

Clinical Trials

Doxorubicin and Bortezomib in Treating Patients With Liver Cancer Start of enrollment: 2004 Mar 01
Completed
Phase 2
Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors Start of enrollment: 2007 Jul 01
Terminated
Phase 1
Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer Start of enrollment: 2007 Jun 01
Completed
Phase 1
Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery Start of enrollment: 2011 Dec 12
Completed
Phase 1, Phase 2
Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer Start of enrollment: 2013 Feb 12
Terminated
Phase 1, Phase 2
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer Start of enrollment: 2012 Nov 23
Completed
Phase 2
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 1
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer Start of enrollment: 2013 Sep 01
Completed
Phase 1
Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors Start of enrollment: 2014 Aug 01
Terminated
Phase 1
First in Human Study of M4344 in Participants With Advanced Solid Tumors Start of enrollment: 2015 Jan 26
Completed
Phase 1
Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies Start of enrollment: 2016 Nov 01
Terminated
Phase 1, Phase 2
Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer Start of enrollment: 2017 Aug 23
Active, not recruiting
Phase 1, Phase 2
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer Start of enrollment: 2020 Nov 16
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

7 citations
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours.
Howard A Burris, Jordan Berlin, Tobias Arkenau, Gregory M Cote, Martijn P Lolkema
British Journal of Cancer. 2024-04-01
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study.
Do-Youn Oh, Maria Alsina Maqueda, David I Quinn, Peter J O'Dwyer, Ian Chau
BMC Cancer. 2023-11-03
6 citations
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance.
Christina Yap, Jan Rekowski, Moreno Ursino, Olga Solovyeva, Dhrusti Patel
BMJ. 2023-10-20

Lectures

Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer.
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
Expanding the Treatment Landscape in Hepatocellular Carcinoma
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Great Debates and Updates in Gastrointestinal Malignancies
Imedex, New York, New York - 3/30/2012
5th Symposium on Emerging Treatments & Advances in Novel Cancer Therapies for Practicing Physicians & Healthcare Professionals
CancerNet, LLC, Dallas, Texas - 1/18/2012
Join now to see all